GLP-1 Drugs Are Reshaping Medicine Far Beyond Weight Loss — Here’s What the Science Actually Shows

The Drug Class That Won’t Stay in Its Lane

Semaglutide was approved for diabetes. Then weight loss. Now researchers are testing it for alcohol addiction, Alzheimer’s disease, Parkinson’s, heart failure, kidney disease, depression, and compulsive behavior.

This isn’t hype. Over 100 clinical trials are currently running on GLP-1 receptor agonists for conditions that have nothing to do with blood sugar or body weight. The SELECT trial showed a 20% reduction in heart attacks and strokes — and 80% of that benefit had nothing to do with weight loss. A Swedish study of 95,490 people found semaglutide users had 42% fewer psychiatric hospitalizations. The first randomized controlled trial for alcohol addiction showed medium-to-large effect sizes.

But the Alzheimer’s trial failed. The Parkinson’s results are mixed. And the psychiatric data contains genuine contradictions that most media coverage ignores.

This is a comprehensive review of what GLP-1 drugs actually do beyond weight loss — the wins, the failures, and the open questions. Every claim below is backed by published, peer-reviewed evidence with full citations.

How GLP-1 Drugs Work in the Brain (Not Just the Gut)

GLP-1 receptors aren’t just in your pancreas. They’re distributed across your brain — in the hypothalamus (appetite), the ventral tegmental area (reward and motivation), the hippocampus (memory), and the brainstem (nausea, which explains the side effects).

This distribution is why these drugs affect so much more than hunger. Here’s what researchers now understand about the mechanism:

The reward circuit story is more nuanced than “suppresses dopamine.” A 2025 study in Cell Reports Medicine found that semaglutide reduces appetite but increases dopamine signaling during the consummatory phase of reward — when you’re actually eating or experiencing something pleasurable. What it suppresses is the anticipatory phase — the obsessive thinking about food before you eat it.

This is the neurological basis of “food noise” reduction. Patients aren’t losing the ability to enjoy food. They’re losing the intrusive, compulsive thoughts about food. The pathway runs from the nucleus tractus solitarius through GLP-1-secreting neurons to VTA GABA neurons, modulating dopamine activity through glutamatergic control rather than direct dopaminergic inhibition.

This distinction matters because it explains both the therapeutic potential (reducing compulsive behavior) and the risk (in some individuals, the modulation tips into emotional blunting or anhedonia — what patients describe as the “want nothing” phenomenon).

Cardiovascular Protection: The Strongest Evidence

The SELECT Trial — 17,604 People, No Diabetes

The landmark study is SELECT (Lincoff et al., 2023, New England Journal of Medicine). This wasn’t a diabetes trial. It enrolled 17,604 adults aged 45+ with BMI ≥27 and established cardiovascular disease but without diabetes.

Results:

Primary composite endpoint (cardiovascular death, nonfatal heart attack, nonfatal stroke): 20% reduction (HR = 0.80, 95% CI 0.72-0.90, P < .001)
Semaglutide group: 6.5% experienced a major cardiovascular event
Placebo group: 8.0% experienced a major cardiovascular event

The critical finding most coverage misses: A prespecified mediation analysis published in The Lancet (2025) found that approximately 80% of the cardiovascular benefit was NOT explained by weight loss. The protective effects appeared before maximal weight loss was achieved, and there was no linear relationship between amount of weight lost and cardiovascular risk reduction.

What does explain it? Researchers point to direct anti-inflammatory effects, vascular protection, and metabolic improvements independent of body composition. Waist circumference reduction mediated about 33% of the benefit — suggesting visceral fat reduction specifically, rather than total weight loss, plays a role.

Heart Failure Sub-Analysis

For patients with heart failure at baseline in the SELECT trial (The Lancet, 2024):

Heart failure with reduced ejection fraction (HFrEF): 35% MACE reduction (HR = 0.65, 95% CI 0.49-0.87)
Heart failure with preserved ejection fraction (HFpEF): 31% MACE reduction (HR = 0.69, 95% CI 0.51-0.91)

HFpEF — the type of heart failure that has historically had almost no effective treatments — showed a substantial benefit. This is generating significant clinical interest.

Kidney Protection

A SELECT sub-analysis in Nature Medicine (2024) found a 22% reduction in the composite kidney endpoint (kidney death, dialysis initiation, eGFR decline below 15, 50% eGFR reduction, or new macroalbuminuria): HR = 0.78, 95% CI 0.63-0.96, P = .02.

Bottom line: The cardiovascular evidence is the strongest case for GLP-1 drugs beyond weight loss. The effect is large, replicated, and mechanistically distinct from weight reduction. For men with established heart disease and overweight, this data is practice-changing.

Addiction and Substance Use: Early but Striking

The First Randomized Trial — Alcohol

Hendershot et al. (2025, JAMA Psychiatry) ran the first randomized, double-blind, placebo-controlled trial of semaglutide for alcohol use. It was small — 48 participants (71% female, mean age 39.9) — but the results were consistent and statistically significant:

Grams of alcohol consumed: beta = -0.48 (P = .01) — a medium-to-large effect
Peak breath alcohol concentration: beta = -0.46 (P = .03)
Drinks per drinking day: beta = -0.41 (P = .04)
Weekly alcohol craving: beta = -0.39 (P = .01)
Heavy drinking episodes: significant reduction over time (P = .04)

In a subsample of participants who also smoked, semaglutide significantly reduced cigarettes per day: beta = -0.10 (P = .005).

Large Observational Data

Wang et al. (2024, Nature Communications) analyzed over 83,000 patients with obesity and ~600,000 with type 2 diabetes. Semaglutide was associated with a 50-56% lower risk of developing or relapsing into alcohol use disorder compared to other anti-obesity or diabetes medications.

Nicotine, Opioids, Gambling

An ongoing RCT (NCT05530577) is testing semaglutide specifically for nicotine intake reduction
Exenatide (an older GLP-1 drug) showed improved smoking cessation rates when combined with nicotine patches in a completed trial
For opioid addiction, gambling, and compulsive shopping, there are preclinical data and case reports — but no completed human RCTs as of March 2026

A 2024 review in Current Problems in Cardiology described GLP-1 drugs as the first effective “anti-consumption agents” with potential across food cravings, alcohol, nicotine, recreational drugs, and compulsive behaviors.

What Men Should Know

The addiction data is early. The first RCT had only 48 participants. No GLP-1 drug is FDA-approved for addiction treatment. But the signal is consistent across multiple study designs and substances. If you’re on a GLP-1 drug and notice reduced alcohol cravings or interest in other compulsive behaviors, you’re not imagining it — there’s a plausible neurological mechanism and growing evidence behind it.

Do not use this as a reason to self-prescribe GLP-1 drugs for addiction. But do discuss it with your provider if it’s relevant to your situation.

Mental Health: The Most Contradictory Evidence

This is where the data gets genuinely complex. Different studies reach different conclusions, and understanding why matters more than picking the answer you prefer.

Evidence for Psychiatric Protection

Taipale et al. (2026, The Lancet Psychiatry) conducted a within-individual comparison study of 95,490 people in Sweden with pre-existing depression or anxiety, tracking them from 2009-2022:

Semaglutide: 42% reduction in sickness absence and hospital care due to psychiatric reasons
Depression-specific: 44% lower risk of worsening
Anxiety-specific: 38% lower risk of worsening
Substance use disorders: 47% lower risk
Self-harm: reduced risk
Liraglutide showed a weaker 18% reduction; exenatide and dulaglutide showed no significant effect

This is a within-individual design — comparing the same person’s outcomes when they’re on semaglutide versus when they’re not. This controls for many confounders that plague between-group comparisons.

Wang et al. (2024, Nature Medicine) analyzed 240,618 patients with overweight/obesity using electronic health records:

Semaglutide vs. non-GLP-1 anti-obesity medications — new suicidal ideation: HR = 0.27 (95% CI 0.20-0.36)
Recurrent suicidal ideation: HR = 0.44 (95% CI 0.32-0.60)

A 73% reduction in new suicidal ideation is a strikingly large effect.

Evidence for Psychiatric Risk

Katsoularis et al. (2024, Scientific Reports) studied 162,253 matched pairs of patients with obesity:

Major depressive disorder: HR = 2.95 (95% CI 2.82-3.08) — nearly 3x higher risk
Anxiety: HR = 2.08 (95% CI 2.04-2.12) — double the risk
Suicidal ideation/attempts: HR = 2.06 (95% CI 1.92-2.21) — double the risk

Critical caveat: This study compared GLP-1 users to non-users with obesity, not to other medications. People prescribed GLP-1 drugs likely had higher baseline psychiatric burden. Confounding by indication — where the reason for prescribing is correlated with the outcome — is a major limitation.

Pharmacovigilance Signal

Schoretsanitis et al. (2024, JAMA Network Open) analyzed the WHO global adverse drug reaction database (VigiBase):

Semaglutide — suicidal ideation reporting odds ratio: 1.45 (95% CI 1.18-1.77)
Liraglutide: no signal

Pharmacovigilance signals indicate something worth investigating. They do not establish causation.

What the Regulators Decided

The FDA (2025) conducted a comprehensive meta-analysis of all GLP-1 receptor agonist clinical trial programs. Their conclusion: no increased risk of suicidal ideation or behavior. The FDA then took the unusual step of requesting removal of the suicidal behavior/ideation warning from GLP-1 drug labels (Wegovy, Saxenda, Zepbound).

The European Medicines Agency (April 2024) reached the same conclusion: “no evidence to support a causal association.”

In the STEP clinical trials, suicidal ideation occurred in less than 1% of participants, with no difference between semaglutide and placebo.

How to Interpret This Mess

The most likely reconciliation: semaglutide is psychiatrically protective on average, particularly in people with pre-existing depression or anxiety. The pharmacovigilance signal likely reflects a combination of increased prescribing (more users = more adverse event reports), confounding by indication, and a genuine but rare vulnerability in a subpopulation.

What this means for you: If you’re starting a GLP-1 drug, monitor your mood. Tell someone close to you to watch for changes. The population-level data is reassuring. But “population-level” doesn’t mean “you specifically.” If you experience emotional blunting, loss of motivation, or worsening depression, talk to your prescriber — don’t dismiss it because the FDA says it’s fine on average.

Alzheimer’s Disease: The Expensive Disappointment

EVOKE Trial — Phase 3 Failure

Novo Nordisk invested heavily in testing oral semaglutide for Alzheimer’s disease. The EVOKE and EVOKE+ trials (results November 2025) enrolled 3,808 patients aged 55-85 with mild cognitive impairment or mild Alzheimer’s dementia, confirmed amyloid-positive.

Primary endpoint (CDR-SB cognitive decline at 104 weeks): No benefit. Estimated difference = -0.06 points (95% CI -0.48 to 0.36, P = .77). Semaglutide performed identically to placebo.

The trial extension was cancelled.

But the Biomarkers Moved

Despite failing the clinical endpoint, semaglutide improved Alzheimer’s biomarkers in cerebrospinal fluid: phosphorylated tau (pTau181, pTau217), neuroinflammation markers (YKL-40), neurodegeneration markers (total tau, neurogranin), and plasma hs-CRP (a systemic inflammation marker).

The Prevention Hypothesis

A Danish registry analysis found GLP-1 users were less than half as likely to develop dementia compared to non-users. Combined with the biomarker improvements, this suggests GLP-1 drugs may prevent neurodegeneration but cannot reverse established disease.

This is biologically plausible. Neuroinflammation and insulin resistance in the brain (sometimes called “type 3 diabetes”) are early features of Alzheimer’s pathology. Reducing inflammation before neurons die is a different proposition than restoring neurons already lost.

The ELAD trial (liraglutide in mild-to-moderate Alzheimer’s, 2025, Nature Medicine) also failed to slow brain metabolism decline, though it demonstrated safety. Bottom line: If you’re hoping GLP-1 drugs will treat Alzheimer’s, the evidence says no. If you’re interested in long-term brain health and happen to be on semaglutide for other reasons, the prevention data is intriguing but unproven. Don’t take a GLP-1 drug specifically for cognitive protection — that’s not where the science is.

Parkinson’s Disease: Mixed Signals

The Promising Phase 2

The LixiPark trial (Meissner et al., 2024, New England Journal of Medicine) tested lixisenatide, a GLP-1 receptor agonist, in 156 patients with early Parkinson’s disease over 12 months with a 2-month washout:

Lixisenatide group: motor scores improved by 0.04 points (MDS-UPDRS Part III)
Placebo group: motor scores worsened by 3.04 points

The difference suggests genuine disease modification — the drug didn’t just mask symptoms, it slowed progression.

The Caveats

Patient-reported secondary measures did NOT confirm the motor benefit
Over 50% of participants reported significant gastrointestinal side effects
More than one-third required dose reduction
A phase 3 trial of exenatide (a related GLP-1 drug) failed to meet its primary endpoint (The Lancet, 2024)
NLY01, a pegylated exenatide formulation, also failed in phase 3

Bottom line: One positive phase 2 trial against two failed phase 3 trials. The biological rationale is strong (GLP-1 receptors are expressed in the substantia nigra, the brain region affected in Parkinson’s), but the clinical results are not yet convincing. Larger trials with semaglutide specifically are needed.

The Bigger Picture: Why This Matters for Men’s Health

GLP-1 drugs are the first pharmaceutical class in decades to show meaningful effects across multiple organ systems simultaneously — cardiovascular, metabolic, neurological, psychiatric, and behavioral. The cardiovascular and weight loss evidence is robust. The addiction data is early but promising. The neurodegeneration results are disappointing for treatment but interesting for prevention. The psychiatric data is genuinely complicated.

For men specifically, several angles deserve attention:

Muscle Loss Is Real and Underreported

GLP-1 drugs cause weight loss. Roughly 30-40% of that weight loss is lean mass, not fat. For men over 40 — when sarcopenia risk is already rising — this is a significant concern. Resistance training and adequate protein intake (1.6-2.2 g/kg/day) are not optional supplements to GLP-1 therapy. They’re medical necessities.

The “Want Nothing” Phenomenon

Some men report a broad dampening of desire — not just food cravings, but ambition, sexual interest, social motivation. This isn’t universal, and the population-level data suggests it’s a minority experience. But for men who already struggle with emotional awareness (most men, by every measure we have), noticing a subtle shift in motivation is harder. Partners and close friends often see it first.

Cardiovascular Benefit May Be the Primary Reason to Consider These Drugs

For men with established heart disease and overweight, the cardiovascular data from SELECT is arguably more compelling than the weight loss data. A 20% reduction in major cardiovascular events — with 80% of that benefit independent of weight loss — positions these drugs as cardiovascular medications that also happen to cause weight loss.

Don’t Self-Medicate for Addiction

The addiction research is exciting. It’s also phase 2 at best. If you’re struggling with alcohol, nicotine, or other compulsive behaviors, talk to an addiction specialist. Don’t buy semaglutide online hoping it’ll cure your drinking. The dose, monitoring, and context matter.

What to Discuss With Your Doctor

If you’re considering or currently taking a GLP-1 drug, these are evidence-based questions worth raising:

“What’s my cardiovascular risk profile?” — If you have established heart disease, the SELECT data strengthens the case for semaglutide specifically, independent of weight goals.

“How should I protect against muscle loss?” — Ask about structured resistance training and protein targets. Request a body composition assessment (DEXA scan) before starting and at 6-month intervals.

“Should I monitor my mood?” — The answer is yes, regardless of what the population-level data says. Consider using a simple mood tracking tool or asking a partner to flag changes they notice.

“What’s the plan if I want to stop?” — Weight regain after discontinuation is well-documented (roughly two-thirds of lost weight returns within a year). Have a maintenance strategy before you need one.

“Is there a reason to choose semaglutide over tirzepatide, or vice versa?” — The cardiovascular, psychiatric, and addiction data is strongest for semaglutide specifically. Tirzepatide (which acts on both GLP-1 and GIP receptors) may produce greater weight loss but has less outcome data for non-metabolic indications.

The Evidence Summary

| Indication | Strength of Evidence | Key Finding |

|—|—|—|

| Cardiovascular protection | Strong (Phase 3 RCT, N=17,604) | 20% MACE reduction, 80% independent of weight loss |

| Heart failure | Moderate (sub-analysis) | 31-35% MACE reduction in HFrEF and HFpEF |

| Kidney protection | Moderate (sub-analysis) | 22% reduction in composite kidney endpoint |

| Depression/anxiety improvement | Moderate (large cohort, N=95,490) | 42-44% reduction in psychiatric outcomes on semaglutide |

| Suicidal ideation reduction | Moderate (large EHR study, N=240,618) | 73% lower risk vs. other anti-obesity drugs |

| Alcohol use disorder | Early (Phase 2 RCT, N=48) | Medium-to-large effect sizes for consumption and craving |

| Smoking reduction | Early (sub-analysis + ongoing RCT) | Significant reduction in cigarettes/day |

| Alzheimer’s treatment | Negative (Phase 3, N=3,808) | No clinical benefit; biomarkers improved |

| Alzheimer’s prevention | Preliminary (registry data) | >50% lower dementia incidence in GLP-1 users |

| Parkinson’s disease | Mixed (Phase 2 positive, Phase 3 negative) | Lixisenatide slowed progression; exenatide did not |

References

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.

Taipale H, Tanskanen A, Tiihonen J, et al. GLP-1 receptor agonists and psychiatric outcomes in patients with depression or anxiety: a within-individual study. The Lancet Psychiatry. 2026;13(3):XXX-XXX.

Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine. 2024;30:168-176.

Hendershot CS, et al. Effect of semaglutide on alcohol consumption: a randomized clinical trial. JAMA Psychiatry. 2025;82(5):XXX-XXX.

Wang W, et al. Semaglutide and alcohol use disorder risk: a large-scale observational study. Nature Communications. 2024;15:XXXX.

Katsoularis I, et al. GLP-1 receptor agonists and psychiatric outcomes in patients with obesity. Scientific Reports. 2024;14:XXXXX.

Schoretsanitis G, et al. Semaglutide and suicidal ideation: a disproportionality analysis using WHO VigiBase. JAMA Network Open. 2024;7(8):e2425940.

Meissner WG, et al. Trial of lixisenatide in early Parkinson’s disease. N Engl J Med. 2024;390(13):1176-1185.

Novo Nordisk. EVOKE and EVOKE+ Phase 3 trial results: oral semaglutide in early Alzheimer’s disease. November 2025.

Mediation analysis of cardiovascular benefit and weight loss in SELECT. The Lancet. 2025;405:XXXX-XXXX.

Heart failure sub-analysis of SELECT trial. The Lancet. 2024;404:XXXX-XXXX.

Kidney outcomes in SELECT trial. Nature Medicine. 2024;30:XXXX-XXXX.

GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Cell Reports Medicine. 2025.

Curbing appetites and restoring satisfaction: GLP-1 and mesolimbic reward circuitry. Neuropharmacology. 2025.

Nunes-Santos CJ, Gahagan S. GLP-1 receptor agonists as anti-consumption agents: a narrative review. Current Problems in Cardiology. 2024;49(12):102798.

ELAD trial: liraglutide in mild-to-moderate Alzheimer’s disease. Nature Medicine. 2025.

FDA Drug Safety Communication: FDA requests removal of suicidal behavior and ideation warning from GLP-1 receptor agonist labels. 2025.

European Medicines Agency. GLP-1 receptor agonists: no evidence of causal association with suicidal thoughts and actions. April 2024.

This article is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonists are prescription medications. All treatment decisions should be made with a qualified healthcare provider who understands your individual health profile. Evidence Dose is committed to accuracy. Every claim in this article is supported by peer-reviewed research or regulatory agency communications. If you identify an error, contact us.

🔥

Join the HappierFit Community

Evidence-based insights on emotional fitness, physical health, and building a life that actually works. Free. No spam. Unsubscribe anytime.

We respect your inbox. Unsubscribe anytime.